Live Breaking News & Updates on O Scyx Us8112922005

Stay updated with breaking news from O scyx us8112922005. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

GSK to exclusively license novel oral antifungal

GSK is set to gain exclusive rights to first-in-class oral antifungal Brexafemme for vulvovaginal candidiasis from SCYNEXIS. The exclusive licence agreement will enable GSK to commercialise. | March 30, 2023 ....

Luke Miels , Drug Administration , Russell Publishing , World Health Organization , Chief Commercial Officer , Health Organization , European Pharmaceutical , Russell Publishing Limited , Nc Stock Exchange , Press Release , O Scyx Us8112922005 ,